Forget UnitedHealth: Humana Has More to Lose From CMS’s Medicare Advantage Audit Crackdown

Wiltone Asuncion • 6 minute read
Reviewed by: Michael Douglass
Last updated Nov 20, 2026

@jittawit21 from jittawit21 via Canva; @aukidphumsirichat via Canva

Key Takeaways

  • UnitedHealth fell 5% on Tuesday after CMS proposed applying Medicare Advantage audit findings to whole contracts, going back to payment year 2018. Humana and CVS Health fell with it, and Humana dropped another 13% on Wednesday.
  • Humana has more at stake: 83% of its 2025 premiums and services revenue came from federal contracts, while CMS premiums made up 44% of UnitedHealth’s revenue.
  • With a 2.5% operating margin in 2025, Humana would feel the same audit roughly 3x as hard as UnitedHealth.
  • Smaller plans like Alignment Healthcare have even less margin, and Humana’s 22x forward P/E, still above its five-year average, leaves little room for the risk.

UnitedHealth Group (UNH) got the headlines when it sank 5% on Tuesday, Nov. 17. The Centers for Medicare & Medicaid Services (CMS) had just proposed widening its audits of Medicare Advantage plans. Humana (HUM) and CVS Health (CVS), which owns Aetna, fell with it. The selling deepened on Wednesday, when Humana dropped 13%, more than UnitedHealth’s 10%.

UnitedHealth may be the largest Medicare Advantage insurer, but Humana has the most to lose. Smaller plans like Alignment Healthcare (ALHC) have even less margin to absorb a hit.

CMS wants its money back, all the way to 2018

CMS calls the proposal CRUSH. Under the proposed rule, audits that check medical records against the diagnoses plans are paid for would apply the error rate from a sample of charts to the plan’s whole contract, starting with payment year 2018. CMS estimates that would recover about $9 billion per payment year across the industry.

Humana has fought this before. It sued over CMS’s 2023 version of the extrapolation rule, and a federal judge in Texas threw that rule out in September 2025, finding that it wasn’t a logical outgrowth of what CMS had proposed, so the industry never got proper notice. The government appealed that November, and the Fifth Circuit heard arguments on Oct. 5, 2026, but hasn’t ruled. CRUSH puts the same approach back on the table.

TIKR tracks 26 analysts on UnitedHealth. How many say “Buy”?

See the full breakdown of Buy, Hold, and Sell ratings on UnitedHealth, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See UnitedHealth’s Analyst Ratings

83% of Humana’s revenue comes from the government doing the auditing

Humana’s annual report says 83% of its 2025 premiums and services revenue came from contracts with the federal government. UnitedHealth deals with the same agency, but CMS premiums were 44% of its 2025 revenue, since it also runs employer insurance, Medicaid plans and Optum. CVS spreads the risk wider still, with Aetna beside its pharmacies and its pharmacy benefit manager.

Analysts expect Humana’s federal business to drive a big rebound, with normalized EPS bottoming at $9.54 this year and reaching $36.91 by 2028, nearly 4x as much:

Bar chart from TIKR of Humana's normalized EPS, actual and consensus estimates, $ per share, fiscal 2023-2028.
Humana (HUM): normalized EPS, actual and consensus estimates, $ per share, fiscal 2023-2028 (TIKR)

Those estimates largely predate the proposal, and CMS hasn’t sized the clawback for any single insurer yet.

A 2.5% margin doesn’t leave much room

Humana’s operating margin fell from 6.5% in 2020 to 2.5% in 2025:

Line chart from TIKR of Humana's operating (EBIT) margin (%), fiscal 2016-2025.
Humana (HUM): operating (EBIT) margin (%), fiscal 2016-2025 (TIKR)

If an audit took back 1% of each company’s federal revenue, Humana would lose 0.83% of its total revenue, about a third of its 2.5% operating margin. UnitedHealth would lose 0.44%, about a tenth of its 4.2% GAAP operating margin for 2025. By that rough math, the same audit hits Humana roughly 3x as hard.

Alignment is in a tighter spot. It grew third-quarter revenue 36.7% to $1.36 billion but lost $3.8 million from operations, and its adjusted EBITDA margin was 1.6%. A company running that close to breakeven has very little room to absorb years of clawbacks.

Humana still isn’t cheap

Even after a three-day slide that left it at $380.00 on Thursday, down 17.6% from its Nov. 16 close, Humana trades at about 22x forward earnings, above its five-year average of 20x:

Line chart from TIKR of Humana's forward (NTM) P/E, last 5 years.
Humana (HUM): forward (NTM) P/E, last 5 years (TIKR)

The next twelve months are mostly 2027, when analysts expect $18.45 a share, half of 2028’s $36.91. So the price rests on a 2028 recovery that depends on the same agency that now wants money back.

It’s still only a proposal. CMS’s $9 billion a year covers the whole industry, and not every federal dollar Humana earns is within an audit’s reach. But until this is settled, every payment year from 2018 on is a possible liability for Humana, which has less margin to cover it than UnitedHealth does.

UnitedHealth took the headline, but Humana is the stock this rule could hurt most, and even after the selloff, its price doesn’t leave much room for that. The tests are the comment deadline on Jan. 19, 2027, the Fifth Circuit’s ruling on Humana’s court win, and Humana’s 2027 guidance early next year. A guide that holds near the $18.45 analysts expect, with a number on its audit exposure, would ease the worry. Silence on the exposure would not.

So what is Humana stock actually worth?

TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what Humana could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.

Value Humana for free

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!

Join thousands of investors worldwide who use TIKR to supercharge their investment analysis.

Sign Up for FREENo credit card required